Skip to main content
Premium Trial:

Request an Annual Quote

Global Genomics, Metabolon Collaborate on Coronary Disease Biomarkers

NEW YORK (GenomeWeb News) – Global Genomics Group and Metabolon today announced a collaboration aimed at discovering novel biomarkers and drug targets for cardiovascular diseases.

As part of the deal, Metabolon will use its TrueVision metabolomics offering to analyze biochemicals for a study called Genetic Loci and Burden of Atherosclerotic Lesions, or GLOBAL. The study combines genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, and lipoprotein proteomics with coronary computed tomographic angiography.

The TrueVision platform comprises mass spectroscopy for analytical chemistry, informatics, and biological expertise for measuring and interpreting the concentrations of biochemicals and metabolites.

Metabolon will use its metabolomics platform and targeted assays to complement the other omics technologies being used in GLOBAL, Global Genomics CEO and Co-founder Szilard Voros said, adding the study is expected to encompass the analysis of 22 trillion data points from the CT phenotyping and "the complete pan-omic analysis to decode the complex biology underlying atherosclerotic disease to identify new drug targets and biomarkers."

GLOBAL will enroll 7,500 patients in its first phase and may be expanded to include 10,000 patients in Phase II, Voros said. More than 3,000 patients have been enrolled so far.

Global Genomics is funding GLOBAL, which is being carried out in partnership with Health Diagnostic Laboratory.